NASDAQ$SAGE
Sage Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Sage Therapeutics reported Q2 2025 total revenues of $31.7M with a net loss of $49.7M and diluted EPS of $(0.79).
Total revenues were $31.7 million, primarily collaboration revenue related to ZURZUVAE with Biogen. Net loss was $49.7 million, or $0.79 per diluted share, as the company prioritized PPD commercialization and pipeline prioritization after discontinuing ZULRESSO.
- Q2 total revenues $31.7M.
- Net loss $49.7M; diluted EPS $(0.79).
- ZURZUVAE PPD launch with Biogen is strategic focus.
- R&D spend on SAGE-319 and platform candidates.
Headline financials
Revenue & EPS history
Sage · Revenue · Quarterly
$31.7M
Revenue by segment
Sage · $1.64M total across 1 segment · Q4 2021
- ZULRESSO Net Revenue$1.64M—100.0%
Forward guidance
Healthcare outlook emphasizes reimbursement, pipeline milestones, and path to profitability.
Tailwinds
- Product launches and partnership economics.
- Cost discipline and cash runway.
Headwinds
- Clinical, regulatory, and pricing risk.
- Operating losses until scale is reached.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
-2.8%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-6.4%
Avg return
30 days after
43%
19 / 44 earnings
Positive
+12.4%
Q4 2021
Best reaction
-47.6%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | -4.1% | -5.7% | -15.0% | |
| Q4 2024 | -0.4% | -0.8% | +7.2% | |
| Q3 2024 | -24.6% | -29.1% | -35.2% | |
| Q2 2024 | -9.6% | -17.2% | -22.1% | |
| Q1 2024 | -2.2% | -0.6% | -19.4% | |
| Q4 2023 | +10.4% | +1.3% | -13.2% | |
| Q3 2023 | -10.2% | -17.1% | +1.3% | |
| Q2 2023 | -47.6% | -39.7% | -42.8% | |
| Q1 2023 | -2.4% | +0.9% | +1.9% | |
| Q4 2022 | +0.9% | -5.2% | -5.2% | |
| Q3 2022 | -5.0% | +5.0% | +16.5% | |
| Q2 2022 | +4.6% | +21.6% | +12.8% | |
| Q1 2022 | +4.9% | -12.2% | +12.6% | |
| Q4 2021 | +12.4% | +12.3% | -1.0% | |
| Q3 2021 | +11.2% | +6.4% | -9.7% | |
| Q2 2021 | -4.0% | -5.1% | +9.0% | |
| Q1 2021 | -10.3% | — | — | |
| Q4 2020 | +4.0% | — | — | |
| Q3 2020 | -0.6% | — | — | |
| Q2 2020 | +1.3% | — | — | |
| Q1 2020 | -4.1% | — | — | |
| Q4 2019 | -26.2% | — | — | |
| Q3 2019 | -0.2% | — | — | |
| Q2 2019 | +7.4% | — | — | |
| Q1 2019 | +0.3% | — | — | |
| Q4 2018 | -8.2% | — | — | |
| Q3 2018 | +3.0% | — | — | |
| Q2 2018 | -0.7% | — | — | |
| Q1 2018 | +1.2% | — | — | |
| Q4 2017 | +0.2% | — | — | |
| Q3 2017 | +11.7% | — | — | |
| Q2 2017 | +7.7% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +0.6% | — | — | |
| Q3 2016 | +0.5% | — | — | |
| Q2 2016 | -13.3% | — | — | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -4.8% | — | — | |
| Q3 2015 | -4.6% | — | — | |
| Q2 2015 | -6.5% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | +2.1% | — | — | |
| Q3 2014 | -5.2% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro